IDEA Collider: Innovation & Asymmetric Learning in Pharma

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Tim Kight,  a long-life student of elite performance, coach, and Focus 3 CEO joins us on the show as we discuss developing leaders & strengthening organizational culture to achieve better results.Tim delves into the five drivers of organizational greatness, training your team on behavioral skills, rebuilding your company’s culture, and expanding your focus run. Additionally, he talks about replacing old habits with good ones, the twenty square ft principle, and stepping up to become an elite in your team! Tune in for more! During this episode, you will learn about;[00:27] Introducing the show[01:50] Tim’s background & experience in sports & business[05:45] Invention doesn’t become innovation all by itself.  What roles teams & organizations play[07:29] 5 drivers for organizational greatness[09:25] Talent recognition in organizations[11:26] What to consider when hiring -Job skills vs. behavior skills. [17:52] Leading with your heart in business[20:43] Rethinking & rebuilding a company’s clear, concise & compelling culture[23:13] A quick contrast between an athletic & business team[26:41] Planning for the future of your business.  The known versus the unknown of the company's future.[31:14] Expanding your focus run & 5 questions to ask yourself and your team[35:50] Unlearning to relearn your skill versus replacing old habits with good ones[38:00] Tim’s twenty square ft principle[45:37] A case study on changing culture, discipline & achieving good results[53:00] Stepping up, confronting that default mode, and becoming elite in your team[55:36] To connect with Tim Kight Don’t forget to Follow, Rate, Review, Like, and Share! Let’s Connect!Follow Tim Kight on;●        LinkedIn: https://www.linkedin.com/in/timothykight/●        Website:  https://focus3.com●        Twitter: @TimothyKight●        Email: tim@foucs3.comMore ProductsFollow Mike Rea on;●        Website: https://www.ideapharma.com/●        Twitter: https://twitter.com/ideapharma●        LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another amazing episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. In today’s episode, Mike is joined by John Waid. John is a thought leader, author, and CEO of a unique boutique global culture & leadership development firm. He talks about culture and the purpose of an organization.Additionally, he talks about the importance of knowing your; purpose, mission, values, and principles of behavior and why most professionals who are promoted based on their skill sets fail when promoted to leadership positions. Moreover, he shares how to start building a successful workplace culture.  Tune in! During this episode, you will learn about;[00:22] Episode introduction[00:36] Today’s focus; Asymmetric learning and its impact on culture[00:55] Know our guest; John Waid[03:01] What is culture?[05:41] The purpose of an organization[10:36] Examples of companies and their values[14:46] Why he came up with the principle of three values[16:34] The importance of respectful spirit value[19:19] Why you should know your; purpose, mission, values, and principles of behavior[22:16] Why most professionals who are promoted based on their skillsets fail when promoted to leadership positions[26:27] Chick-fil-A’s values and culture[32:31] Why one company outperforms the other[37:16] Can culture be built virtually? [40:25] How to start building a successful workplace culture [42:53] Disruption vs Innovation[45:09] How to connect with John Waid  Love the show? Follow, Rate, Review, Like, and Share!  Let’s Connect!Follow John Waid on;Website: https://www.corporatecultureconsulting.com/LinkedIn: https://www.linkedin.com/in/johnwaid/Facebook: https://www.facebook.com/c3culture/ More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by a consultant, best-selling author, and one of the world’s top experts on strategy and innovation, Rita McGrath.In the episode, Rita talks to us about her transition from a political science career to innovation in the corporate venture, how to build an innovation program, challenges in implementation, and why you need multiple funding sources while championing an idea. Additionally, we delve into making that 10x shift in a company, discovery-driven planning, strategic inflection points & best books she would recommend.Tune in for more innovation insights![02:01] About Rita McGrath[05:10] Rita’s books[11:55] Tips for building an innovation program[16:10] Why do companies have one innovation process[18:45] Reasons companies prefer false confidence instead of the uncertain approach[27:40] How to get an organization to make a shift to a big place[34:11] Rita’s thoughts on creativity[37:25] Why you should have multiple sources  of funding & approval[37:54] Being future forward on failure & interrogating failure[43:48] Problems related to assumptions in planning[49:39] Discovery-driven planning[51:01] Strategic inflection points[55:05] Books Rita would recommend[57:16] This or that question (Disruption or innovation)[58:13] To connect with McGrath Mentioned BooksSeeing Around the Corners By Rita McGrathMarket Busters By Rita McGrathThe End of Competitive Advantage By Rita McGrathDiscovery-Driven Growth By Rita McGrathSeven Rules of Power By Jeffrey PfefferThinking Fast & Slow by Kahneman DanielHumor Seriously By Jennifer A Aker & Naomi Bagdonas Let’s Connect!To Connect With Rita McGrath;●    Website: https://www.ritamcgrath.com/●    Website: https://www.valize.com/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Andrew Hopkins, the Founder & CEO  of Exscientia, as he talks to us about the use of AI in drug discovery. In the episode, we delve into Andrew’s journey of developing better drug discovery methods, applying data mining in drug discovery, and the value of data integration in the pharmaceutical industry. Additionally, he expounds on what AI drugs look like and future plans for Exscientia. Tune in! During this episode, you will learn about;[01:12] Introducing Andrew Hopkins & his journey to his current role[06:27] Applying data mining approach & machine learning[12:10] What Andrew saw that others were not seeing[19:06] The value of data integration[22:02] The role of asking questions & finding answers in tech or data[26:46] How Hopkins addresses being referred to as the AI discovery group[33:08] Active learning approaches[39:06] What an AI drug looks like & what it’s better at[42:17] The future of AI drugs & Exscientia future plans in establishing clinics[46:34] What do the next couple of years look like regarding solutions Andrew wished he had 5-10 years ago? Don’t forget to Follow, Rate, Review, Like, and Share! Mentioned BooksIdeas-A History From Fire To Freud by Peter WatsonWhere Good Ideas Come From by Steven Johnson Let’s Connect!Follow Exscientia on;●        Website: https://www.exscientia.ai/●    LinkedIn: https://www.linkedin.com/company/ex-scientia/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

In this incredible episode, Mike Rea is joined by Dr. John L. LaMattina. John is the former Senior Vice President of Pfizer Inc and President of Pfizer Global Research & Development. Additionally, he is a senior partner at PureTech Health and an author. He talks about the misconception about Pfizer’s profiteering from the pandemic and the drug pricing in America. John also discusses how Gilead’s Sovaldi drug for hepatitis C became overpriced in the US and the effects of insurance companies on the drug market. Moreover, he talks about the misinformation about insulin and its pricing, NIH’s role in drug discovery research, and the profitability of the pharma industry.Tune in! During this episode, you will learn about;[00:22] Introduction to the show[0:42] Know our guest; Dr. John L. LaMattina, and why he has authored his books[04:58] Misconception about Pfizer’s profiteering from the pandemic[08:13] Drug pricing in America[12:35] Gilead’s Sovaldi drug for hepatitis C and how it became overpriced in the US more than in other countries [19:57] The cost-effectiveness of PCSK9 in regulating (low-density lipoprotein) LDL cholesterol[21:42] Effect the insurance companies have had on the drug market [26:09] Value of  the ‘me-too’ drugs [30:01] The inefficiency of the flu vaccines [33:03] The funding for early-stage mRNA vaccines [34:23] The input of the FDA and CDC in the manufacture of mRNA vaccines [37:46] What is NIH’s role in drug discovery research?[38:13] The process and cost of drug discovery; from idea to getting the drug approved[42:39] Misinformation about insulin and its pricing [47:21] Is the value vs. affordability of medicines a reputation challenge or a  commercial challenge for the industry?[51:31] What’s the profitability of the pharma industry?[59:48] Recommended reading [01:02:38] How to connect with us Don’t forget to Subscribe, Rate, Review, Like, and Share! Resources MentionedBook; Pharma and Profits by John L. LaMattina Book; Devalued and Distrusted by John L. LaMattinaBook; Drug Truths by John L. LaMattinaBook; The Great American Drug Deal by Peter Kolchinsky  Let’s Connect!Website: https://www.johnlamattina.com/Twitter: https://twitter.com/john_lamattinaLinkedIn: https://www.linkedin.com/in/john-lamattina-2985a9b/ More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another fantastic episode of the IDEA Collider│Asymmetric learning series with your host Mike Rea. Today we are joined by Gene Yoo, the Chief Executive Officer at Resecurity, Inc. He talks about asymmetric learning in cybersecurity & Intelligence and what gives Resecurity an edge over other competitors in the marketMoreover, he shares about the signal validation process at Resecurity, how to understand the vulnerability of your business and what you need to combat cyber threats. In addition, Gene talks about the ‘what if’ component in their learning approach and the leadership style & culture at Resecurity. Tune in! During this episode, you will learn about; [00:23] Introduction to the show[01:23] What this series is about; Asymmetric learning[04:41] Definition of insight in cybersecurity[07:07] What is cyber threat intelligence about, and how should threat intelligence data be interpreted to deliver actionable insights?[10:37] Security theater[14:40] How Resecurity identifies a threat [19:58] Understanding the vulnerability of your business and what you need to combat cyber threats[22:52] Do they provide threat solutions or just threat evidence?[24:22] The ‘what if’ component in their learning approach [27:36] What gives Resecurity an edge over other cybersecurity & Intelligence companies in the market?[29:19] Signal validation process at Resecurity[31:00] The source of their data[34:29] Resecurity leadership style and culture[39:40] Prototyping at Resecurity[42:49] Does Gene prefer a disruptor or an innovator? [44:59] What’s the future of  Resecurity in 5 years? (46:33] How to connect with Gene Yoo Don’t forget to Subscribe, Rate, Review, Like, and Share! Let’s Connect!Follow Gene Yoo on;Website: https://resecurity.com/LinkedIn: https://www.linkedin.com/company/resecurity/Facebook: https://bit.ly/3vqMfzSTwitter: https://twitter.com/RESecurityVimeo: https://vimeo.com/user153388997 More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another fantastic episode of the IDEA Collider│Asymmetric learning series with your host Mike Rea. In today’s episode, Mike interviews Steven Johnson, an author of 13 books, a TV host, and a podcaster. He talks about Innovation vs. Invention and explains where good ideas come from. Additionally, Steven talks about the Individual and organizational hunch collection tools and shares how organizational culture impacts innovation. Moreover, he talks about his books The Ghost Map and Farsighted. Tune in! During this episode, you will learn about;[01:05] Meet Steven Johnson and hear his backstory[03:03] Innovation vs. Invention[05:26] Where do good ideas ‘soul hunches’ come from?[09:32] Reason why play and delight are linked to profound innovation[12:52] Organizational culture and innovation[17:12] How the daily schedule for his writing work looks like [10:1414] Steven’s discovery process[26:59] How Steven uses Twitter as a source of scientific discovery[30:58] Individual and organizational hunch collection tools[39:10] The Ghost Map and how it evolved  from the format to a published book[46:34] Farsighted: How We Make the Decisions That Matter the Most[55:11] How to connect with Steven Johnson Remember to Follow, Rate, Review, Like, and Share! Resources MentionedBook; The Ghost Map by Steven JohnsonBook; Farsighted by Steven JohnsonBook; How We Got to Now by Steven JohnsonBook: Wonderland by Steven Johnson  Let’s Connect!Follow Steven Johnson on;Website: https://stevenberlinjohnson.com/Twitter: https://twitter.com/stevenbjohnsonSubscribe to his Newsletter at: https://adjacentpossible.substack.com/aboutTo grab a copy of any of Steven’s Books: https://amzn.to/3L3zUrV More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another fantastic episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Billy Kenber, an investigative journalist at “The Times.” He talks about his journey to writing his book ‘Sick Money’ and the content in the book.Additionally, he talks about the pharmaceutical industry’s social contract with patients and how its distortion has led to pharmaceutical greed. Moreover, he shares how the culture within the pharmaceutical industry has changed, why drug companies overprice the drugs, and what can be done to regulate drug pricing. Tune in! During this episode, you will learn about; [00:22] Episode introduction[01:08] Meet our guest; Billy Kenber[01:22] His journey to writing his book ‘Sick Money’[03:28] What the book is about[06:11] How Concordia Pharmaceuticals & Valeant Pharmaceuticals companiesgrew quickly and gained a short-term monopoly, thus hiking the drug prices[10:40] What’s the geographical scope of the pharmaceutical fraud[12:47] Pharmaceutical industry’s social contract with patients and how its distortion has led to pharmaceutical greed[15:20] The first AIDS drug; AZT[18:30] A background of AZT drug high pricing and how it led to otherpharmaceutical companies raising their prices[22:47] How Pharmacy Benefit Managers (PBMs) raise drug prices for patients[25:39] The ’Dirty Pharma’ chapter in his book[28:45] Why drug companies overprice the drugs[29:17] How the culture within the pharmaceutical industry has changed[30:52] Pharmaceutical innovation after World War II; Antibiotics[35:29] mRNA vaccines in the COVID-19 pandemic[37:28] Effect of cultural changes in the pharmaceutical industry on the drugs weget and how Research and Development (R&D) is done[40:30] How cultural changes have affected orphan drugs and cancer drugs[46:30] What can be done to regulate drug pricing?[53:50] Recommended reading[56:00] How to connect with Billy Love the show? Follow, Rate, Review, Like, and Share! Let’s Connect! Follow Billy Kenber on his;Website: https://www.billykenber.com/  Twitter: https://twitter.com/billykenber Linkt.ree: https://linktr.ee/billykenber To grab a copy of the ‘Sick Money’ book: https://amzn.to/3N4XJPD More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/ Twitter: https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Kabir Nath is President & CEO, Otsuka North America Pharmaceutical Business Throughout his career, Kabir has built bridges between cultures. His work has taken him across the globe, spanning 3 continents and multiple countries. Kabir has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. He has consistently inspired those around him to go beyond cultural and linguistic differences to bring new concepts and ideas to life, forging stronger partnerships rooted in diverse experiences. For Kabir, leadership is not about having all the answers, rather, it is about creating an environment where Otsuka-people are deeply connected to their purpose, and the patients and families they serve. In his nearly 30 years of broad international biopharmaceutical and medical-device experience, Kabir has shaped strategy to deliver results in complex, challenging business environments at the country, regional, and global level. Otsuka, with its unique blend of Japanese and American cultures, is the place where Kabir puts his purpose into practice daily. Kabir joined Otsuka in March 2016 to head all commercial operations within the North American pharmaceutical businesses. Most recently, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business at Otsuka, with overall operational leadership for the global pharmaceutical business, overseeing North America, Europe, Japan, and the rest of Asia, while continuing to have direct responsibility for the US business. Before joining Otsuka, Kabir held strategic and senior operational roles across several continents at Bristol-Myers Squibb (BMS). He began his career in strategy consulting at Booz Allen & Hamilton before holding a wide range of operational and strategic roles at the medical technology company Smith + Nephew. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.